Royalty Pharma PLC
NASDAQ:RPRX
Intrinsic Value
Royalty Pharma Plc provides drug development services. [ Read More ]
The intrinsic value of one RPRX stock under the Base Case scenario is 49.064 USD. Compared to the current market price of 27.675 USD, Royalty Pharma PLC is Undervalued by 44%.
Valuation Backtest
Royalty Pharma PLC
Run backtest to discover the historical profit from buying and selling RPRX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Royalty Pharma PLC
Current Assets | 1.3B |
Cash & Short-Term Investments | 1.2B |
Receivables | 36.6m |
Other Current Assets | 3.8m |
Non-Current Assets | 15.1B |
Long-Term Investments | 15.1B |
Other Non-Current Assets | 6.5m |
Current Liabilities | 161.4m |
Accounts Payable | 15.2m |
Accrued Liabilities | 51.7m |
Other Current Liabilities | 94.5m |
Non-Current Liabilities | 9.7B |
Long-Term Debt | 6.1B |
Other Non-Current Liabilities | 3.6B |
Earnings Waterfall
Royalty Pharma PLC
Revenue
|
2.4B
USD
|
Operating Expenses
|
-862.4m
USD
|
Operating Income
|
1.5B
USD
|
Other Expenses
|
-357.3m
USD
|
Net Income
|
1.1B
USD
|
Free Cash Flow Analysis
Royalty Pharma PLC
What is Free Cash Flow?
RPRX Profitability Score
Profitability Due Diligence
Royalty Pharma PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
Score
Royalty Pharma PLC's profitability score is 57/100. The higher the profitability score, the more profitable the company is.
RPRX Solvency Score
Solvency Due Diligence
Royalty Pharma PLC's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Score
Royalty Pharma PLC's solvency score is 40/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
RPRX Price Targets Summary
Royalty Pharma PLC
According to Wall Street analysts, the average 1-year price target for RPRX is 46.41 USD with a low forecast of 37.37 USD and a high forecast of 63 USD.
Ownership
RPRX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
RPRX Price
Royalty Pharma PLC
Average Annual Return | -2.2% |
Standard Deviation of Annual Returns | 11.01% |
Max Drawdown | -48% |
Market Capitalization | 16.5B USD |
Shares Outstanding | 597 430 000 |
Percentage of Shares Shorted | 2.89% |
RPRX News
Last Important Events
Royalty Pharma PLC
Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.
Sentiment Analysis
Royalty Pharma PLC
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Royalty Pharma Plc provides drug development services. The company is headquartered in New York City, New York and currently employs 66 full-time employees. The company went IPO on 2020-06-16. The firm invests in academic institutions, research hospitals and not-for-profits from small and mid-cap biotechnology companies to global pharmaceutical companies. The Company’s portfolio of pharmaceutical investments includes investments in commercial products and development-stage product candidates. Its portfolio investments include AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko, Trikafta, OXLUMO and five development-stage product candidates.
Contact
IPO
Employees
Officers
The intrinsic value of one RPRX stock under the Base Case scenario is 49.064 USD.
Compared to the current market price of 27.675 USD, Royalty Pharma PLC is Undervalued by 44%.